抗ウイルス薬市場：世界の産業規模、シェア、動向、機会、予測、タイプ別、薬剤クラス別、流通チャネル別、用途別、地域別、競合別、2019年～2029年

抗ウイルス薬の世界市場規模は2023年に760億1,000万米ドルとなり、2029年までの予測期間のCAGRは0.55%で着実な成長が予測されています。

抗ウイルス薬の世界市場は、人体内でのウイルスの複製を阻害することで、ウイルス感染と闘うために処方された医薬品で構成されています。これらの医薬品は、ウイルスの侵入、複製、放出を含むウイルス複製サイクルの特定の段階を標的とするように設計されており、それによってウイルス感染の増殖を阻害し、人体への悪影響を軽減します。HIV/AIDS、肝炎、インフルエンザ、ヘルペス、COVID-19のような呼吸器系ウイルスなどの疾患にまたがる、世界のウイルス感染の急増は、抗ウイルス薬の需要を促進しています。ウイルスの大流行、パンデミック、感染症の出現は、抗ウイルス治療薬に対する意識を高め、投資を刺激します。

ウイルス学と薬理学の絶え間ない進歩は、研究開発の継続的な努力を促し、新規抗ウイルス薬の発見と革新を促進します。ハイスループット・スクリーニング、分子モデリング、構造ベースの薬剤設計などの最先端技術を活用することで、研究者は有効性と安全性を高めた有望な薬剤候補を同定しています。高齢化社会、特に新興経済諸国では、加齢に伴う免疫機能の低下により、ウイルス感染に対する脆弱性が高まっています。高齢者人口が世界的に拡大するにつれて、高齢者のウイルス性疾患や合併症に対処するための抗ウイルス薬に対するニーズが高まり、市場における抗ウイルス薬の需要が拡大しています。

主な市場促進要因

ウイルス感染の有病率の増加

研究開発の進展

新興市場におけるヘルスケアインフラの拡大

主な市場課題

ウイルス耐性と変異の多様性

薬剤開発コストと市場開拓期間

規制上のハードルと市場アクセス

主な市場動向

抗ウイルス薬の発見と開発の進歩

適応症と治療法の拡大

併用療法とマルチターゲットアプローチへのシフト

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の抗ウイルス薬市場の見通し

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（ブランド、ジェネリック）
  • 薬剤クラス別（DNAポリメラーゼ阻害剤、逆転写酵素阻害剤、プロテアーゼ阻害剤、ノイラミニダーゼ阻害剤、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 用途別（HIV、肝炎、ヘルペス、インフルエンザ、その他）
  • 地域別
  • 企業別（2023）
• 市場マップ

第6章 北米抗ウイルス薬市場の見通し

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 薬剤クラス別
  • 流通チャネル別
  • 用途別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の抗ウイルス薬市場の見通し

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 薬剤クラス別
  • 流通チャネル別
  • 用途別
  • 国別
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋の抗ウイルス薬市場の見通し

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 薬剤クラス別
  • 流通チャネル別
  • 用途別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の抗ウイルス薬市場の見通し

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 薬剤クラス別
  • 流通チャネル別
  • 用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東およびアフリカの抗ウイルス薬市場の見通し

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 薬剤クラス別
  • 流通チャネル別
  • 用途別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の抗ウイルス薬市場：SWOT分析

第14章 競合情勢

• F. Hoffmann-La Roche Ltd
• GSK plc.
• AbbVie, Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Aurobindo Pharma
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Anti Viral Drugs Market has valued at USD 76.01 billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 0.55% through 2029. The global market for antiviral drugs comprises pharmaceutical products formulated to combat viral infections by hindering the replication of viruses within the human body. These medications are engineered to target specific stages of the viral replication cycle, including viral entry, replication, and release, thereby impeding the proliferation of viral infections and mitigating their adverse effects on human health. The surge in viral infections worldwide, spanning diseases such as HIV/AIDS, hepatitis, influenza, herpes, and respiratory viruses like COVID-19, propels the demand for antiviral drugs. Viral outbreaks, pandemics, and the emergence of infectious diseases elevate awareness and stimulate investments in antiviral therapeutics.

Continuous advancements in virology and pharmacology drive ongoing research and development endeavors, fostering the discovery and innovation of novel antiviral drugs. Leveraging cutting-edge technologies like high-throughput screening, molecular modeling, and structure-based drug design, researchers identify promising drug candidates with enhanced efficacy and safety profiles. The aging population, particularly in developed economies, exhibits heightened vulnerability to viral infections due to age-related declines in immune function. As the elderly demographic expands globally, there arises a heightened need for antiviral medications to address viral illnesses and complications among older adults, thus amplifying the demand for such drugs in the market.

Key Market Drivers

Increasing Prevalence of Viral Infections

The escalating incidence of viral infections worldwide, including diseases such as HIV/AIDS, hepatitis, influenza, herpes, and respiratory viruses like COVID-19, drives the demand for effective antiviral medications. Viral outbreaks, pandemics, and the emergence of new infectious diseases underscore the urgent need for therapies capable of combating viral pathogens and reducing their impact on public health. The growing prevalence of viral infections expands the patient population in need of antiviral treatment. This includes individuals affected by chronic viral illnesses, acute infections, and immunocompromised patients at heightened risk of viral complications. The expanding patient pool drives market demand for a diverse range of antiviral drugs tailored to different viral pathogens and patient populations.

Viral infections impose a significant healthcare burden on healthcare systems globally, necessitating effective treatment options to alleviate disease burden and improve patient outcomes. The economic costs associated with viral outbreaks, including healthcare expenditures, lost productivity, and societal impacts, underscore the importance of investing in antiviral therapies capable of mitigating disease transmission and reducing healthcare resource utilization. The increasing prevalence of viral infections highlights the importance of public health preparedness and response measures to mitigate the spread of infectious diseases. Antiviral drugs play a critical role in disease containment strategies, including outbreak control, contact tracing, and treatment of infected individuals. Governments, healthcare organizations, and pharmaceutical companies invest in antiviral drug development and stockpiling initiatives to enhance readiness for future viral outbreaks and pandemics.

Regulatory agencies provide incentives for the development and approval of antiviral drugs to address unmet medical needs and public health challenges posed by viral infections. Expedited review pathways, priority review designations, and regulatory approvals for antiviral therapies targeting emerging infectious diseases facilitate market access and accelerate the commercialization of novel treatments. The increasing prevalence of viral infections drives the growth of the global antiviral drugs market by fueling demand for effective treatment options, expanding the patient population in need of antiviral therapy, imposing a healthcare burden that necessitates intervention, highlighting the importance of public health preparedness, and incentivizing regulatory approvals for antiviral medications. These factors underscore the significance of antiviral drugs in addressing public health challenges posed by viral diseases and driving market growth in the pharmaceutical industry.

Advancements in Research and Development

Continual advancements in virology and pharmacology enable researchers to identify novel drug targets within viral replication cycles. Through in-depth understanding of viral pathogenesis and host-virus interactions, researchers pinpoint vulnerabilities in viral mechanisms that can be exploited for therapeutic intervention. This knowledge fuels the discovery of new antiviral drug candidates with potent and selective mechanisms of action. Advancements in drug discovery technologies, such as high-throughput screening, molecular modeling, and structure-based drug design, revolutionize the process of identifying and optimizing antiviral drug candidates. These innovative platforms enable rapid screening of large compound libraries, prediction of drug-target interactions, and design of structurally diverse molecules with improved pharmacokinetic properties and therapeutic efficacy.

Innovations in drug formulation technologies facilitate the development of optimized formulations for antiviral drugs, improving their stability, bioavailability, and tissue targeting properties. Novel drug delivery systems, including nanoparticles, liposomes, and polymer-based carriers, enable targeted delivery of antiviral agents to specific viral reservoirs or anatomical sites, enhancing therapeutic outcomes while minimizing systemic side effects. Advances in personalized medicine and pharmacogenomics enable tailored treatment strategies based on individual genetic profiles, disease characteristics, and treatment responses. Genetic biomarkers associated with viral susceptibility, drug metabolism, and treatment efficacy inform the selection of optimal antiviral therapies for patients, maximizing therapeutic outcomes and minimizing adverse reactions.

Streamlined drug development pipelines, facilitated by regulatory incentives, collaborative research networks, and public-private partnerships, expedite the translation of promising antiviral drug candidates from preclinical research to clinical trials and market approval. Fast-track regulatory pathways, priority review designations, and orphan drug designations incentivize investment in antiviral drug development and accelerate market access for innovative therapies targeting unmet medical needs. Advancements in research and development drive the growth of the global antiviral drugs market by enabling the discovery of novel drug targets, development of innovative drug platforms, enhancement of drug formulations and delivery systems, implementation of personalized medicine approaches, and acceleration of drug development pipelines. These advancements underpin the evolution of antiviral therapeutics and contribute to the expansion of treatment options for viral infections, thereby driving market growth in the pharmaceutical industry.

Expansion of Healthcare Infrastructure in Emerging Markets

High-throughput screening technologies enable the rapid screening of large compound libraries to identify potential antiviral drug candidates. Automated assay systems coupled with advanced robotics allow for the simultaneous testing of thousands of compounds, accelerating the discovery process and increasing the likelihood of identifying hits with antiviral activity. Molecular modeling techniques leverage computational algorithms to simulate the interactions between antiviral drug candidates and their target viral proteins. Virtual screening methods prioritize compounds with favorable binding properties, guiding the selection of lead molecules for experimental validation. These approaches streamline the drug discovery process, facilitating the design of novel antiviral agents with enhanced potency and specificity.

Structure-based drug design utilizes three-dimensional structural information of viral proteins to design small molecule inhibitors with precise binding interactions. X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and cryo-electron microscopy enable the determination of high-resolution structures, providing insights into the molecular mechanisms of viral replication and pathogenesis. SBDD approaches enable the rational design of antiviral drugs targeting specific viral enzymes or structural proteins, leading to the development of highly selective therapeutics with improved efficacy and reduced off-target effects. Combinatorial chemistry techniques allow for the rapid synthesis of diverse chemical libraries containing millions of unique compounds. Parallel synthesis methodologies enable the generation of compound libraries with structural diversity, facilitating the identification of novel antiviral scaffolds through iterative optimization cycles. Library synthesis approaches accelerate hit-to-lead optimization efforts, expediting the development of lead compounds with desirable pharmacological properties for further preclinical evaluation.

Artificial intelligence (AI) and machine learning algorithms analyze large datasets to predict the bioactivity, pharmacokinetics, and safety profiles of potential antiviral compounds. These computational models leverage data-driven insights to prioritize lead optimization strategies, identify structure-activity relationships, and predict compound properties with high accuracy. AI-driven drug discovery platforms enhance decision-making processes, enabling researchers to navigate complex chemical space and accelerate the development of next-generation antiviral therapies. Technological innovations in drug development drive the growth of the global antiviral drugs market by enabling high-throughput screening, molecular modeling, structure-based drug design, combinatorial chemistry, and AI-driven drug discovery. These advancements streamline the drug discovery process, expedite lead identification and optimization, and facilitate the development of novel antiviral therapies with improved efficacy and safety profiles, thereby fueling market growth in the pharmaceutical industry.

Key Market Challenges

Viral Resistance and Mutational Variability

Viral resistance poses a significant challenge to the effectiveness of antiviral drugs. Viruses have the ability to mutate rapidly, leading to the emergence of drug-resistant strains that render existing antiviral medications ineffective. This phenomenon is particularly problematic in the case of chronic viral infections such as HIV/AIDS and hepatitis, where prolonged drug exposure increases the likelihood of resistance development. Additionally, the high mutational variability of RNA viruses like influenza and coronaviruses presents challenges in the design of antiviral therapies targeting conserved viral proteins or genomic regions.

The emergence of drug-resistant viral strains diminishes the effectiveness of existing antiviral drugs, leading to treatment failure and disease progression in affected individuals. Healthcare providers face challenges in managing drug-resistant viral infections, requiring alternative treatment regimens or combination therapies to overcome resistance and achieve virological suppression. Drug-resistant viruses pose a public health threat by undermining disease control efforts and increasing the risk of viral transmission within communities. Resistant strains may spread globally, complicating outbreak containment and pandemic response strategies.

Drug Development Costs and Time-to-Market

The development of novel antiviral drugs is a resource-intensive process that requires significant investments of time, capital, and expertise. Research and development activities, including preclinical studies, clinical trials, regulatory submissions, and manufacturing scale-up, incur substantial costs and entail lengthy timelines. Moreover, the high failure rates associated with drug development pipelines further compound the financial risks faced by pharmaceutical companies investing in antiviral research.

The high cost of drug development and the uncertain return on investment deter pharmaceutical companies from pursuing antiviral research, particularly for diseases with limited market potential or uncertain commercial viability. Lengthy regulatory approval processes and post-marketing surveillance requirements prolong the time-to-market for new antiviral drugs, delaying patient access to innovative therapies and limiting revenue generation opportunities for drug developers. Intense competition among pharmaceutical companies vying for market share in the antiviral drugs market intensifies pricing pressures and profit margins, further challenging the sustainability of drug development initiatives.

Regulatory Hurdles and Market Access

Regulatory requirements governing the approval, marketing, and distribution of antiviral drugs vary across different regions and jurisdictions, posing challenges for market access and commercialization. Stringent regulatory standards, complex approval pathways, and evolving regulatory guidelines necessitate robust clinical development programs and comprehensive regulatory submissions to demonstrate the safety, efficacy, and quality of antiviral therapies.

Ambiguities in regulatory guidelines and evolving requirements pose challenges for drug developers seeking regulatory approval for antiviral drugs, leading to delays in product development and market entry. Disparate regulatory frameworks across international markets create barriers to market entry for antiviral drugs, requiring companies to navigate complex regulatory landscapes and tailor strategies to meet diverse regulatory requirements. Market access for antiviral drugs may be hindered by reimbursement restrictions, formulary decisions, and payer policies that limit patient access to costly therapies or favor lower-priced alternatives, impacting the commercial viability of antiviral drug products.

Key Market Trends

Advancements in Antiviral Drug Discovery and Development

Continuous advancements in drug discovery technologies and research methodologies are revolutionizing the development of antiviral drugs. Emerging approaches such as structure-based drug design, high-throughput screening, and virtual screening are enabling the rapid identification and optimization of novel drug candidates with enhanced efficacy and safety profiles. Additionally, innovative platforms leveraging artificial intelligence (AI) and machine learning algorithms are accelerating the identification of potential antiviral compounds and predicting their pharmacological properties, streamlining the drug development process.

The adoption of advanced drug discovery technologies expands the antiviral drug pipeline, facilitating the development of next-generation therapies targeting a broad spectrum of viral pathogens. Novel antiviral drugs with optimized pharmacokinetic properties and mechanisms of action offer improved treatment outcomes, including higher efficacy, reduced toxicity, and enhanced patient adherence. Precision medicine approaches based on genetic biomarkers and viral genotyping enable the personalized selection of antiviral therapies tailored to individual patient characteristics and disease profiles, maximizing treatment effectiveness and minimizing adverse effects.

Expansion of Indications and Therapeutic Applications

Antiviral drugs are increasingly being investigated for their potential therapeutic applications beyond traditional viral infections. Emerging research areas include the repurposing of antiviral agents for the treatment of non-viral diseases such as cancer, autoimmune disorders, and neurodegenerative diseases. Additionally, antiviral drugs are being explored for prophylactic use in high-risk populations to prevent viral transmission and reduce the burden of infectious diseases.

The expansion of indications broadens the market potential for antiviral drugs, creating new revenue streams and growth opportunities for pharmaceutical companies. Collaborative research initiatives between virologists, oncologists, immunologists, and neuroscientists drive innovation in antiviral drug development and foster interdisciplinary approaches to disease management. The repurposing of antiviral drugs for non-viral indications offers novel therapeutic options for patients with unmet medical needs, potentially improving treatment outcomes and quality of life.

Shift Towards Combination Therapies and Multi-Target Approaches

The emergence of drug-resistant viral strains and the complexity of viral replication pathways necessitate innovative treatment strategies to overcome therapeutic challenges. Combination therapies involving the concurrent administration of multiple antiviral drugs with distinct mechanisms of action are gaining prominence as a means to enhance treatment efficacy, prevent drug resistance, and reduce viral load. Additionally, multi-target approaches targeting multiple viral proteins or pathways are being explored to maximize antiviral activity and minimize the risk of treatment failure.

Combination therapies exploit synergistic interactions between different antiviral agents, leading to enhanced antiviral activity and improved treatment outcomes compared to monotherapy regimens. Simultaneous targeting of multiple viral targets reduces the likelihood of resistance development and improves the durability of treatment response, prolonging the effectiveness of antiviral therapies. Tailored combination regimens allow for personalized treatment approaches based on viral genotype, drug susceptibility, and patient-specific factors, optimizing therapeutic responses and minimizing side effects.

Segmental Insights

Type Insights

Based on the category of Type, the branded segment emerged as the dominant in the global market for antiviral drugs market in 2023. Branded antiviral drugs often enjoy greater recognition and reputation compared to generic alternatives. Pharmaceutical firms heavily invest in marketing and promotional activities to establish brand awareness and differentiate their products in the competitive market landscape. This strong brand equity boosts consumer confidence and physician preference, resulting in increased demand for branded antiviral medications. These drugs are frequently protected by patents and market exclusivity rights, granting pharmaceutical companies exclusive manufacturing, marketing, and sales rights for a specified duration. This patent protection safeguards against generic competition, allowing brand manufacturers to maintain pricing power and market share, thereby maximizing revenue potential and profitability throughout the product lifecycle.

Branded antiviral medications often incorporate proprietary formulations, innovative delivery systems, and novel technologies, setting them apart from generic counterparts. Pharmaceutical firms invest in research and development to introduce product enhancements, extended-release formulations, and combination therapies that provide additional therapeutic benefits and improve patient outcomes. This product innovation enhances the perceived value of branded antiviral drugs and sustains their competitive advantage in the market. Physicians commonly prefer prescribing branded antiviral drugs over generics due to their familiarity, perceived efficacy, and clinical experience. Pharmaceutical sales representatives engage in detailing activities to educate healthcare providers about the benefits of branded medications, influencing prescribing decisions and driving the uptake of branded antiviral therapies in the market. Physician loyalty to established brands further contributes to the dominance of branded antiviral drugs in clinical practice.

Branded antiviral drugs typically command premium pricing compared to generic equivalents, reflecting the expenses associated with research and development, marketing, and brand building endeavors. Pharmaceutical firms employ pricing strategies to maximize profitability while ensuring market access and affordability for patients through initiatives such as patient assistance programs, discounts, and reimbursement support. Differential pricing strategies enable branded manufacturers to capture value across diverse market segments and geographical regions, thus sustaining their dominance in the global antiviral drugs market. These factors are expected to drive the growth of this segment.

Regional Insights

North America emerged as the dominant in the global antiviral drugs market in 2023, holding the largest market share in terms of value. North America possesses a highly developed healthcare infrastructure, featuring advanced medical facilities, research institutions, and pharmaceutical firms. This robust system facilitates efficient drug development, clinical research, and market entry for antiviral medications. Additionally, stringent regulatory frameworks and streamlined approval processes ensure the prompt introduction of new antiviral therapies, propelling market growth in the region. North America faces a considerable disease burden from viral infections like HIV/AIDS, hepatitis, influenza, and respiratory viruses. Factors such as an aging population, lifestyle choices, and dense population contribute to the prevalence of viral diseases, necessitating widespread utilization of antiviral drugs for treatment and prevention. Moreover, North America ranks among the top regions globally in healthcare expenditure, with significant investments in pharmaceutical research, development, and promotional activities.

North America serves as a global center for biomedical research and innovation, with leading academic institutions, research labs, and pharmaceutical corporations driving advancements in antiviral drug discovery and development. The region's scientific prowess, access to funding, and collaborative research networks foster innovation in virology, pharmacology, and drug delivery technologies. Consequently, North American pharmaceutical firms lead the charge in developing novel antiviral therapies, leveraging state-of-the-art technologies and research insights to tackle unmet medical needs and combat emerging viral threats. Additionally, North America hosts numerous multinational pharmaceutical companies with extensive product portfolios and market dominance in the antiviral drugs sector. These industry giants utilize their resources, expertise, and marketing prowess to dominate the North American market and expand their global reach. Moreover, strategic alliances, licensing agreements, and acquisitions enable North American pharmaceutical firms to penetrate new markets, diversify product offerings, and uphold their competitive edge in the global antiviral drugs market.

Key Market Players

F. Hoffmann-La Roche Ltd

GSK plc.

AbbVie, Inc.

Merck & Co., Inc.

Johnson & Johnson Services, Inc.

Bristol-Myers Squibb Company

Aurobindo Pharma

Cipla Limited

Dr. Reddy's Laboratories Ltd.

Report Scope:

In this report, the Global Antiviral Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antiviral Drugs Market, By Type:

Branded Generics

Antiviral Drugs Market, By Drug Class:

DNA Polymerase Inhibitors Reverse Transcriptase Inhibitors Protease Inhibitors Neuraminidase Inhibitors Others

Antiviral Drugs Market, By Distribution Channel:

Hospital Pharmacy Retail Pharmacy Online Pharmacy

Antiviral Drugs Market, By Application:

HIV Hepatitis Herpes Influenza Others

Antiviral Drugs Market, By Region:

North America
• United States
• Canada
• Mexico
Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
South America
• Brazil
• Argentina
• Colombia
Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antiviral Drugs Market.

Available Customizations:

Global Antiviral Drugs market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antiviral Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Branded, Generic)
  • 5.2.2. By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 5.2.4. By Application (HIV, Hepatitis, Herpes, Influenza, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2023)
• 5.3. Market Map

6. North America Antiviral Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Application
  • 6.2.5. BY Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Antiviral Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Distribution Channel
      • 6.3.1.2.4. By Application
  • 6.3.2. Canada Antiviral Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Distribution Channel
      • 6.3.2.2.4. By Application
  • 6.3.3. Mexico Antiviral Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Distribution Channel
      • 6.3.3.2.4. By Application

7. Europe Antiviral Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Application
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Antiviral Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Distribution Channel
      • 7.3.1.2.4. By Application
  • 7.3.2. United Kingdom Antiviral Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Distribution Channel
      • 7.3.2.2.4. By Application
  • 7.3.3. Italy Antiviral Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Distribution Channel
      • 7.3.3.2.4. By Application
  • 7.3.4. France Antiviral Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Drug Class
      • 7.3.4.2.3. By Distribution Channel
      • 7.3.4.2.4. By Application
  • 7.3.5. Spain Antiviral Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Drug Class
      • 7.3.5.2.3. By Distribution Channel
      • 7.3.5.2.4. By Application

8. Asia-Pacific Antiviral Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Application
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Antiviral Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Distribution Channel
      • 8.3.1.2.4. By Application
  • 8.3.2. India Antiviral Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Distribution Channel
      • 8.3.2.2.4. By Application
  • 8.3.3. Japan Antiviral Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Distribution Channel
      • 8.3.3.2.4. By Application
  • 8.3.4. South Korea Antiviral Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Drug Class
      • 8.3.4.2.3. By Distribution Channel
      • 8.3.4.2.4. By Application
  • 8.3.5. Australia Antiviral Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Drug Class
      • 8.3.5.2.3. By Distribution Channel
      • 8.3.5.2.4. By Application

9. South America Antiviral Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Application
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Antiviral Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Distribution Channel
      • 9.3.1.2.4. By Application
  • 9.3.2. Argentina Antiviral Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Class
      • 9.3.2.2.3. By Distribution Channel
      • 9.3.2.2.4. By Application
  • 9.3.3. Colombia Antiviral Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Distribution Channel
      • 9.3.3.2.4. By Application

10. Middle East and Africa Antiviral Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Drug Class
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Application
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Antiviral Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Drug Class
      • 10.3.1.2.3. By Distribution Channel
      • 10.3.1.2.4. By Application
  • 10.3.2. Saudi Arabia Antiviral Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Drug Class
      • 10.3.2.2.3. By Distribution Channel
      • 10.3.2.2.4. By Application
  • 10.3.3. UAE Antiviral Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Drug Class
      • 10.3.3.2.3. By Distribution Channel
      • 10.3.3.2.4. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Anti Viral Drugs Market: SWOT Analysis

14. Competitive Landscape

• 14.1. F. Hoffmann-La Roche Ltd
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Key Personnel
  • 14.1.5. SWOT Analysis
• 14.2. GSK plc.
• 14.3. AbbVie, Inc.
• 14.4. Merck & Co., Inc.
• 14.5. Johnson & Johnson Services, Inc.
• 14.6. Bristol-Myers Squibb Company
• 14.7. Aurobindo Pharma
• 14.8. Cipla Limited
• 14.9. Dr. Reddy's Laboratories Ltd.

15. Strategic Recommendations

16.About Us & Disclaimer